GlassScriptPhysician profile
Dijo Joseph
NPI 1548766256
$4,445.95
in general payments reported to CMS, 2019-2025
19 companies · $2,430 in 2025
The $2,430 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $142 · 2024: $1,874 · 2025: $2,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,326 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,325.97 |
| Education | $119.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,075.60 | 2024-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $908.22 | 2024-2025 | |
| Amgen INC. | $778.12 | 2023-2025 | Krystexxa, Enbrel, Otezla |
| Ucb, INC. | $513.92 | 2024-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $192.14 | 2023-2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $175.41 | 2024-2025 | Saphnelo |
| Radius Health, INC. | $169.90 | 2024-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $103.33 | 2024-2025 | Idacio, Tyenne |
| Pfizer INC. | $93.34 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $84.46 | 2024-2025 | |
| Lilly USA, LLC | $71.26 | 2024 | Taltz |
| Glaxosmithkline, LLC. | $55.70 | 2024-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.90 | 2024 | Cyltezo |
| Aurinia Pharma U.S., INC. | $46.90 | 2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $37.78 | 2025 | Acthar |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $36.71 | 2025 | Teriparatide |
| Genzyme Corporation | $23.22 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.75 | 2025 | Cuvitru |
| Sobi, INC | $14.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dijo Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.